Loading...

FITC anti-human/mouse Granzyme B Antibody

Pricing & Availability
Clone
GB11 (See other available formats)
Regulatory Status
RUO
Other Names
Granzyme-2, serine protease B, CCP1, Asp-ase, CTLA-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_GB11_FITC_082409
Human peripheral blood lymphocytes surface stained with CD8 PE, then intracellular stained with GB11 FITC
  • A_GB11_FITC_082409
    Human peripheral blood lymphocytes surface stained with CD8 PE, then intracellular stained with GB11 FITC
  • B_GB11_FITC_082409
    Human peripheral blood lymphocytes surface stained with CD8 PE, then intracellular stained with mouse IgG1 FITC isotype control
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
515403 25 tests 108€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Granzyme B is a 32 kD serine protease, also known as granzyme-2, serine protease B, CCP1, Asp-ase, and CTLA-1. Granzyme B is abundantly stored in the granules of cytotoxic T lymphocytes and NK cells. Low level of expression has been reported in granulocytes, B cells, and activated dendritic cells. Granzyme B is crucial for rapid induction of cell death and apoptosis through interaction with mannose-6-phosphate receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse
Reported Reactivity
Rat
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application References
  1. Wever PC, et al. 1998. Immunology. 93:383
  2. Arens R, et al. 2004. J. Exp. Med. 199:1595
  3. Lima M, et al. 2003. Am. J. Pathol. 163:763
  4. Wiede F, et al. 2014. J Autoimmun. 53:105. PubMed
  5. Baker GF, et al. 2014. Cancer Res. 74:5079. PubMed
  6. Nacer A, et al. 2014. PLoS Pathog. 10:1004528. PubMed
  7. Sharma SK, et al. 2015. J Immunol. 194:5529. PubMed
Product Citations
  1. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  2. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  3. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  4. AbuEid M, et al. 2021. iScience. 24(6):102653. PubMed
  5. Donnarumma T, et al. 2016. Cell Rep. 17:1571-1583. PubMed
  6. Baker G, et al. 2014. Cancer Res. 74:5079. PubMed
  7. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  8. Wang W, et al. 2022. World J Gastrointest Oncol. 14:1124. PubMed
  9. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  10. Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed
  11. Shen T, et al. 2019. Cell Death Discov. 5:123. PubMed
  12. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  13. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  14. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  15. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  16. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  17. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  18. Figueroa-Romero C, et al. 2022. Front Immunol. 13:773288. PubMed
  19. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  20. Di Blasi D, et al. 2019. Cell Mol Gastroenterol Hepatol. 0.510416667. PubMed
  21. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  22. Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed
  23. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  24. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  25. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  26. Wu W, et al. 2020. Oncol Lett. 0.91875. PubMed
  27. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  28. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  29. Jiang P, et al. 2021. Nat Methods. 18:1181. PubMed
  30. Islas-Vazquez L, et al. 2020. Biology (Basel). 9:00. PubMed
  31. Kreutmair S, et al. 2021. Immunity. . PubMed
  32. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  33. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  34. Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed
  35. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  36. Fujigaki J, et al. 2015. PLoS One. 10: 0132521. PubMed
  37. Bastiaens G, et al. 2016. Am J Trop Med Hyg. 94: 663 - 673. PubMed
  38. Wiedemann GM, et al. 2020. Cell Rep. 33:108498. PubMed
  39. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  40. Huang CH, et al. 2020. Adv Ther (Weinh). 3:. PubMed
  41. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  42. Xu S, et al. 2021. Immunity. . PubMed
  43. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  44. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  45. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  46. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  47. Vardam-Kaur T, et al. 2021. Oncotarget. 12:2051. PubMed
  48. Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed
  49. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  50. Luo Y, et al. 2021. Nat Commun. 12:3913. PubMed
  51. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  52. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  53. Prado-Garcia H, et al. 2017. Cancer Immunol Immunother. 10.1007/s00262-017-1979-x. PubMed
  54. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  55. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  56. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  57. Jeng MY, et al. 2018. J Exp Med. 215:51. PubMed
  58. Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed
  59. Wiede F, et al. 2014. J Autoimmun. 53:105. PubMed
  60. Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
  61. Kmieciak M, et al. 2011. J Immunol. 187:708. PubMed
  62. Zhang J, et al. 2018. Nature. 553:91. PubMed
  63. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  64. Maleki KT, et al. 2021. Cell Reports Medicine. 2(3):100220. PubMed
  65. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  66. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  67. Lettau M, et al. 2018. Int Immunol. 30:215. PubMed
  68. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  69. Thieme CJ, et al. 2020. Cell Rep Med. 1:100092. PubMed
  70. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  71. Chen RH, et al. 2021. Front Immunol. 11:594775. PubMed
  72. Kansy BA, et al. 2017. Cancer Res. 77:6353. PubMed
  73. Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed
  74. Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed
  75. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  76. Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed
  77. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  78. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  79. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  80. Geary CD et al. 2018. Cell reports. 24(8):1949-1957 . PubMed
  81. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  82. DiMarco AV, et al. 2022. Cancer Immunol Res. 10:70. PubMed
  83. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  84. Li Q, et al. 2022. J Biol Chem. :101753. PubMed
  85. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  86. Vonderhaar EP, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:41. PubMed
  87. Ruth JH, et al. 2021. JCI Insight. 6:e145662. PubMed
  88. Durand J, et al. 2015. J Immunol. 195: 5035 - 5044. PubMed
  89. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  90. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  91. Gorby C, et al. 2020. Sci Signal. :13. PubMed
  92. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  93. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  94. Carrion B, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  95. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  96. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_2114575 (BioLegend Cat. No. 515403)

Antigen Details

Structure
32 kD serine protease
Distribution

Cytotoxic T-cells and NK cells, low on granulocytes, B cells and activated dendritic cells

Function
Induction of cell death and apoptosis
Ligand/Receptor
Mannose-6-phosphate receptor
Cell Type
B cells, Dendritic cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroscience
Molecular Family
Enzymes and Regulators, Proteases
Antigen References

1. Estebanez-Perpina E, et al. 2000. Biol Chem. 381:1203
2. Griffiths GM. And S. Isaaz, et al. 1993. J. Cell Biol. 120:885
3. Spaeny-Dekking EH, et al. 1998. J. Immunol. 160:3610
4. Wagner C, et al. 2008. Mol. Immunol. 45:1761

Gene ID
3002 View all products for this Gene ID 14939 View all products for this Gene ID 171528 View all products for this Gene ID
UniProt
View information about Granzyme B on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 08/25/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account